Innoviva Interest Expense 2011-2026 | INVA

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Innoviva

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
16.7 M	22.2 M	19.2 M	15.8 M	19.1 M	18.3 M	18.7 M	24 M	43.6 M	52.4 M	51.8 M	36.9 M	9.35 M	6 M	6.02 M	6.04 M	6.05 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
52.4 M	6 M	21.9 M

Quarterly Interest Expense Innoviva

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5.44 M	4.02 M	4.66 M	4.71 M	-	5.81 M	5.8 M	5.85 M	-	4.4 M	4.38 M	4.43 M	-	5.1 M	3.66 M	3.01 M	-	4.79 M	4.74 M	4.69 M	-	4.6 M	4.56 M	4.52 M	-	4.69 M	4.66 M	4.62 M	-	5.24 M	6.48 M	7.66 M	-	10.3 M	12.2 M	12.8 M	-	13.1 M	13.2 M	13.2 M	-	13.1 M	13 M	12.7 M	-	12.4 M	10.3 M	1.64 M	-	1.9 M	3.02 M	2.74 M	-	1.5 M	1.5 M	1.5 M	-	1.5 M	1.51 M	1.51 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
13.2 M	1.5 M	6.02 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 3.13	-	$ 651 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 35.0	1.6 %	$ 942 M	USA
Forte Biosciences FBRX	-396 K	$ 22.0	8.32 %	$ 285 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
BioNTech SE BNTX	14.2 M	$ 90.93	0.63 %	$ 22 B	Germany
Autolus Therapeutics plc AUTL	36.7 M	$ 1.65	1.85 %	$ 439 M	Britain
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Heron Therapeutics HRTX	1.34 M	$ 0.87	3.09 %	$ 145 M	USA
Compugen Ltd. CGEN	281 K	$ 2.61	-3.51 %	$ 244 M	Israel
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Incyte Corporation INCY	25.1 M	$ 97.41	0.34 %	$ 19 B	USA
Ionis Pharmaceuticals IONS	17.3 M	$ 75.78	0.96 %	$ 12.1 B	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.44	-0.58 %	$ 5.66 M	Israel
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Coherus BioSciences CHRS	9 M	$ 1.57	3.97 %	$ 184 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 21.01	2.64 %	$ 2.67 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA